Synagis Adverse Event Report 2018

$19.99

This report includes data from the FDA’s Adverse Events Reports for 2018.  We removed reports where the subject of the report was taking only this drug. This report provides the following fields:

  • ID
  • Patient Summary
  • Patient Gender
  • Patient Age
  • Drug Products
  • Drug Reactions

Description

Synagis (palivizumab) is a man-made antibody to respiratory syncytial virus (RSV). RSV can cause serious illness in children. Palivizumab helps keep RSV cells from multiplying in the body. Synagis is used to prevent serious lung disease caused by respiratory syncytial virus in premature infants, and infants born with certain lung disorders or heart disease. Synagis works best in children who are 24 months old or younger at the beginning of RSV season (6 months or younger for premature infants). It will not treat a child who is already sick with RSV disease.https://www.drugs.com/synagis.html

Contact US

484-352-2642

What is an Adverse Event Report?

The FDA Adverse Event Reporting System (FAERS) is a database that contains adverse event reports, medication error reports and product quality complaints resulting in adverse events that were submitted to FDA.